Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | GRM5 | P41594 | 2/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | KDM5A | P29375 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | RHOA | P61586 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320818 | 1.00 | DRD2 (0.56) | DRD2DRD4GLAHSD17B10L3MBTL1 | |
| SCHEMBL3316809 | 1.00 | DRD2 (0.56) | DRD2DRD4GLAHSD17B10L3MBTL1 | |
| SCHEMBL3316814 | 1.00 | DRD2 (0.56) | DRD2DRD4GLAHSD17B10L3MBTL1 | |
| SCHEMBL3320973 | 0.95 | GLA (0.60) | DRD2DRD4GLAHSD17B10L3MBTL1 | |
| SCHEMBL3317199 | 0.95 | GLA (0.60) | DRD2DRD4GLAHSD17B10L3MBTL1 | |
| SCHEMBL3316785 | 0.92 | MEN1 (0.57) | MEN1KMT2AEPHX2KDM5AUSP30 | |
| SCHEMBL3316788 | 0.92 | MEN1 (0.57) | MEN1KMT2AEPHX2KDM5AUSP30 | |
| SCHEMBL3316682 | 0.89 | GRM5 (0.56) | GLAHSD17B10CCR2KMT2AGRM5 | |
| SCHEMBL3316676 | 0.89 | GRM5 (0.56) | GLAHSD17B10CCR2KMT2AGRM5 | |
| SCHEMBL3316668 | 0.89 | GRM5 (0.56) | GLAHSD17B10CCR2KMT2AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123769-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORP (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20130079525-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2013-03-28 | — | — | US | disclosed |
| US-8338142-B2 | Method for producing optically active 3-aminopiperidine or salt thereof | KANEKA CORPORATION (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2123769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | Kaneka Corporation (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079525-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | DRD2 1223/4885DRD4 1032/4885GLA 2225/4885 |
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | DRD2 1223/4885DRD4 1032/4885GLA 2225/4885 |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | DRD2 1223/4885DRD4 1032/4885GLA 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.